Company: PFSA
Filing Date: 2025-10-29
Form Type: 424B3
Source: 0001213900-25-103174
Chunk: 222

Company: Profusa, Inc.
Filing Date: 2025-10-29
Form: 424B3
Chunk 222
---
, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment
centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.

We expect that these initiatives,
as well as other healthcare reform measures that may be adopted in the future, as well as the trend toward managed healthcare and increasing
influence of managed care organizations, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward
pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded
programs may result in a similar reduction in payments from private payors. The implementation of current and future cost containment
measures or other healthcare reforms may adversely affect our operations and prevent us from being able to generate revenue, attain profitability
or commercialize our product candidates.

<div align='center'>130

MANAGEMENT</div>

Directors and Executive Officers

The following table sets forth
the names and ages of all of our directors and executive officers as of April 28, 2025. Our officers are appointed by, and serve
at the pleasure of, the Board of Directors.

| Name                              |     | Age |     | Position                                       |
| Directors and Executive Officers: |     |     |     |                                                |
| Ben C. Hwang, Ph.D.               |     |  57 |     | Chairman of the Board; Chief Executive Officer |
| Fred Knechtel                     |     |  64 |     | Chief Financial Officer                        |
| Rajesh Asorpota                   |     |  56 |     | Director                                       |
| Lauren Chung                      |     |  48 |     | Director                                       |
| Peter O’Rourke                    |     |  52 |     | Lead Independent Director                      |
| Jack Stover                       |     |  71 |     | Director                                       |

The following is information
about the experience and attributes of the members of our board of directors and senior executive officers as of the date of this prospectus.
The experience and attributes of our directors discussed below provide the reasons that these individuals were selected for board membership,
as well as why they continue to serve in such positions.

Ben C. Hwang, Ph.D.— Dr. Hwang has served as Profusa’s Chairman of the Board and Chief Executive Officer since January 2012.
Prior to Profusa, Dr. Hwang served in a variety of leadership roles at Life Technologies Corp. (ac